1-[10-(2-二甲基氨基丙基)吩噻嗪-2-基]丙-1-酮盐酸盐 | 1240-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 中文名称: 1-[10-(2-二甲基氨基丙基)吩噻嗪-2-基]丙-1-酮盐酸盐
• 英文名称: promazine hydrochloride
• 英文别名: 1-[10-(2-dimethylamino-propyl)-phenothiazin-2-yl]-propan-1-one; hydrochloride；1-[10-(2-Dimethylamino-propyl)-phenothiazin-2-yl]-propan-1-on; Hydrochlorid；1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one hydrochloride；1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one;hydron;chloride
• CAS: 1240-15-9
• 化学式: C₂₀H₂₄N₂OS*ClH
• 分子量: 376.95
• InChiKey: UGVNGSMLNPWNNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.25
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  48.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934300000

文献信息

• Anticoagulant contrast media
  申请人：Melton J. Laura

  公开号：US20050281746A1

  公开（公告）日：2005-12-22

  The present invention provides novel anticoagulant contrast agents, which comprise an organic scaffolding moiety, an organic anticoagulant moiety, and an imaging moiety. The invention also provides anticoagulant contrast media and methods of visualizing internal structures utilizing the novel anticoagulant contrast agents and anticoagulant contrast media.

  本发明提供了一种新型抗凝对比剂，包括有机支架基团、有机抗凝基团和成像基团。该发明还提供了抗凝对比介质和利用新型抗凝对比剂和抗凝对比介质来可视化内部结构的方法。
• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Medicinal composition and method of making same
  申请人：Tucker, William Gough

  公开号：EP0212875A2

  公开（公告）日：1987-03-04

  There is disclosed a medicinal composition comprising lipid, non-lipid liquid and pharmaceutical ingredients, characterized by the fact that the ingredients are emulsified and encapsulated in a gelatine capsule as a liquid and in a physical form capable of delivering the pharmaceutical in its unaltered original state to the brush layer of the small intestine; the non-lipid ingredient being water, a water substitute not attacked by lipid enzyme activity or a mixture of water substitute and water; and the total water in the emulsion is not more than 20%; the physical form of the ingredients is as follows: (a) the lipid ingredient is in the form of individual globules predominantly of a size less than about 3 microns in diameter; (b) each of the globules contains the pharmaceutical ingredient dispersed therein; and (c) each of the globules is enveloped within a surrounding layer of said non-lipid liquid ingredient adhered to the globule by surface tension, the surrounding layer serving to maintain the globules in independent form and to present only the non-lipid liquid surface to the stomach fluids. There is also disclosed a method of making same.

  本发明公开了一种由脂质、非脂质液体和药物成分组成的药物组合物，其特征在于这些成分被乳化并以液体的物理形式封装在明胶胶囊中，能够以未改变的原始状态将药物输送到小肠刷状层；非脂质成分是水、未被脂质酶活性攻击的水替代物或水替代物和水的混合物；乳化液中的总水分不超过 20%；成分的物理形式如下： (a) 脂质成分主要呈直径小于约 3 微米的单个球状； (b) 每个小球都含有分散在其中的药物成分；以及 (c) 每个球状物都被包在一层非脂质液体成分的周围层中，这层液体成分通过表面张力附着在球状物上，周围层的作用是保持球状物的独立形态，并使胃液只看到非脂质液体表面。 此外，还公开了一种制作方法。
• An otorhinological drug delivery device
  申请人：Schering Oy

  公开号：EP1438942A1

  公开（公告）日：2004-07-21

  The invention relates to an otorhinological delivery device comprising at least one pharmaceutically active agent. According to the invention the device comprises a core comprising said at least one pharmaceutically active agent wherein said core is made of an elastomer composition selected from the group consisting of poly(dimethylsiloxane), a siloxane-based elastomer comprising 3,3,3-trifluoropropyl groups attached to the Si-atoms of the siloxane units, a siloxane-based elastomer comprising poly(alkylene oxide) groups and mixtures thereof.

  本发明涉及一种包含至少一种药用活性剂的耳鼻喉给药装置。根据本发明，该装置包括一个包含所述至少一种药物活性剂的芯体，其中所述芯体由弹性体组合物制成，该弹性体组合物选自聚（二甲基硅氧烷）、硅氧烷基弹性体（包含连接到硅氧烷单元S原子上的3,3,3-三氟丙基）、硅氧烷基弹性体（包含聚（环氧烷）基团）及其混合物组成的组。
• Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases
  申请人：Combinatorx, Incorporated

  公开号：EP2070550A1

  公开（公告）日：2009-06-17

  The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

  本发明的特点是通过向患者单独或与一种或多种附加制剂联合使用四取代嘧啶嘧啶，治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明的另一个特点是含有四取代嘧啶嘧啶的组合物与一种或多种附加制剂的组合物。